Mike Andriole

Mr. Andriole became President, CEO and a member of the Board of Directors of Chimerix in August 2023.

Prior to becoming President and CEO, Mr. Andriole was Chimerix’s Chief Business Officer and CFO from 2019 to 2023 during which time he led key strategic acquisitions, divestitures and capital raising transactions which reprioritized Chimerix’s pipeline and recapitalized the Company.

Prior to joining Chimerix, Mr. Andriole served as CFO of Endocyte, Inc., a leader in developing targeted treatments for prostate and other cancers where he was instrumental in managing the company through a series of strategic transactions culminating in a sale to Novartis for $2.1 billion, including raising nearly $300 million in capital.

Prior to Endocyte, Mr. Andriole spent 16 years at Eli Lilly and Company in a range of financial, marketing and global business development roles.

Mr. Andriole earned a BSBA from Xavier University’s Williams School of Business and an MBA from Indiana University’s Kelley School of Business.

Categorised in:

This post was written by tbe_admin